nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—RAF1—malignant glioma	0.438	0.591	CbGaD
Dabrafenib—BRAF—malignant glioma	0.304	0.409	CbGaD
Dabrafenib—SLC22A8—choroid plexus—malignant glioma	0.0096	0.203	CbGeAlD
Dabrafenib—Ocular toxicity—Carmustine—malignant glioma	0.00717	0.101	CcSEcCtD
Dabrafenib—Disease progression—Carmustine—malignant glioma	0.00444	0.0624	CcSEcCtD
Dabrafenib—NEK11—medulla oblongata—malignant glioma	0.0031	0.0654	CbGeAlD
Dabrafenib—LIMK1—telencephalon—malignant glioma	0.00282	0.0596	CbGeAlD
Dabrafenib—Haemorrhage intracranial—Temozolomide—malignant glioma	0.00229	0.0321	CcSEcCtD
Dabrafenib—NEK11—cerebellum—malignant glioma	0.00219	0.0462	CbGeAlD
Dabrafenib—LIMK1—midbrain—malignant glioma	0.00203	0.0428	CbGeAlD
Dabrafenib—Lymphopenia—Temozolomide—malignant glioma	0.00183	0.0257	CcSEcCtD
Dabrafenib—Azotaemia—Carmustine—malignant glioma	0.00182	0.0256	CcSEcCtD
Dabrafenib—NEK11—brain—malignant glioma	0.00178	0.0376	CbGeAlD
Dabrafenib—Cerebral haemorrhage—Carmustine—malignant glioma	0.00175	0.0246	CcSEcCtD
Dabrafenib—Cerebral haemorrhage—Temozolomide—malignant glioma	0.00169	0.0238	CcSEcCtD
Dabrafenib—LIMK1—cerebellum—malignant glioma	0.00157	0.0331	CbGeAlD
Dabrafenib—SIK1—telencephalon—malignant glioma	0.00146	0.0308	CbGeAlD
Dabrafenib—Cyst—Carmustine—malignant glioma	0.00145	0.0204	CcSEcCtD
Dabrafenib—RAF1—embryo—malignant glioma	0.00143	0.0301	CbGeAlD
Dabrafenib—RAF1—brainstem—malignant glioma	0.00131	0.0276	CbGeAlD
Dabrafenib—LIMK1—brain—malignant glioma	0.00127	0.0269	CbGeAlD
Dabrafenib—Vaginal haemorrhage—Temozolomide—malignant glioma	0.00127	0.0178	CcSEcCtD
Dabrafenib—BRAF—midbrain—malignant glioma	0.00125	0.0264	CbGeAlD
Dabrafenib—RAF1—telencephalon—malignant glioma	0.00116	0.0245	CbGeAlD
Dabrafenib—Rigors—Temozolomide—malignant glioma	0.00115	0.0161	CcSEcCtD
Dabrafenib—SIK1—medulla oblongata—malignant glioma	0.00115	0.0242	CbGeAlD
Dabrafenib—Gamma-glutamyltransferase increased—Temozolomide—malignant glioma	0.00114	0.016	CcSEcCtD
Dabrafenib—Hyperbilirubinaemia—Temozolomide—malignant glioma	0.00103	0.0145	CcSEcCtD
Dabrafenib—SIK1—spinal cord—malignant glioma	0.00102	0.0216	CbGeAlD
Dabrafenib—BRAF—cerebellum—malignant glioma	0.000969	0.0204	CbGeAlD
Dabrafenib—Phosphatase alkaline increased—Temozolomide—malignant glioma	0.000938	0.0132	CcSEcCtD
Dabrafenib—RAF1—medulla oblongata—malignant glioma	0.000913	0.0193	CbGeAlD
Dabrafenib—Influenza like illness—Temozolomide—malignant glioma	0.000911	0.0128	CcSEcCtD
Dabrafenib—Neoplasm—Carmustine—malignant glioma	0.000877	0.0123	CcSEcCtD
Dabrafenib—Neoplasm—Temozolomide—malignant glioma	0.000848	0.0119	CcSEcCtD
Dabrafenib—RAF1—midbrain—malignant glioma	0.000834	0.0176	CbGeAlD
Dabrafenib—SIK1—central nervous system—malignant glioma	0.00083	0.0175	CbGeAlD
Dabrafenib—RAF1—spinal cord—malignant glioma	0.000814	0.0172	CbGeAlD
Dabrafenib—SIK1—cerebellum—malignant glioma	0.000811	0.0171	CbGeAlD
Dabrafenib—BRAF—brain—malignant glioma	0.000787	0.0166	CbGeAlD
Dabrafenib—Blood alkaline phosphatase increased—Temozolomide—malignant glioma	0.000783	0.011	CcSEcCtD
Dabrafenib—Hyponatraemia—Carmustine—malignant glioma	0.000707	0.00993	CcSEcCtD
Dabrafenib—RAF1—central nervous system—malignant glioma	0.00066	0.0139	CbGeAlD
Dabrafenib—SIK1—brain—malignant glioma	0.000659	0.0139	CbGeAlD
Dabrafenib—RAF1—cerebellum—malignant glioma	0.000645	0.0136	CbGeAlD
Dabrafenib—Hypokalaemia—Carmustine—malignant glioma	0.000641	0.009	CcSEcCtD
Dabrafenib—Dehydration—Temozolomide—malignant glioma	0.000633	0.00888	CcSEcCtD
Dabrafenib—Dry skin—Temozolomide—malignant glioma	0.000624	0.00876	CcSEcCtD
Dabrafenib—Hypokalaemia—Temozolomide—malignant glioma	0.000619	0.00869	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.000613	0.0086	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.0006	0.00843	CcSEcCtD
Dabrafenib—Neutropenia—Carmustine—malignant glioma	0.000569	0.00799	CcSEcCtD
Dabrafenib—Neutropenia—Temozolomide—malignant glioma	0.00055	0.00772	CcSEcCtD
Dabrafenib—Hyperglycaemia—Carmustine—malignant glioma	0.000549	0.00771	CcSEcCtD
Dabrafenib—Renal failure—Carmustine—malignant glioma	0.000534	0.00749	CcSEcCtD
Dabrafenib—Hyperglycaemia—Temozolomide—malignant glioma	0.000531	0.00745	CcSEcCtD
Dabrafenib—Stomatitis—Carmustine—malignant glioma	0.000529	0.00743	CcSEcCtD
Dabrafenib—Urinary tract infection—Carmustine—malignant glioma	0.000528	0.0074	CcSEcCtD
Dabrafenib—Infestation—Temozolomide—malignant glioma	0.000525	0.00736	CcSEcCtD
Dabrafenib—Infestation NOS—Temozolomide—malignant glioma	0.000525	0.00736	CcSEcCtD
Dabrafenib—RAF1—brain—malignant glioma	0.000524	0.0111	CbGeAlD
Dabrafenib—Stomatitis—Temozolomide—malignant glioma	0.000511	0.00718	CcSEcCtD
Dabrafenib—Urinary tract infection—Temozolomide—malignant glioma	0.00051	0.00716	CcSEcCtD
Dabrafenib—SLC22A6—brain—malignant glioma	0.000509	0.0107	CbGeAlD
Dabrafenib—Haemoglobin—Carmustine—malignant glioma	0.00049	0.00687	CcSEcCtD
Dabrafenib—ABCB1—blood vessel—malignant glioma	0.000488	0.0103	CbGeAlD
Dabrafenib—Haemorrhage—Carmustine—malignant glioma	0.000487	0.00684	CcSEcCtD
Dabrafenib—ABCG2—telencephalon—malignant glioma	0.000481	0.0101	CbGeAlD
Dabrafenib—Oedema peripheral—Carmustine—malignant glioma	0.00048	0.00674	CcSEcCtD
Dabrafenib—Connective tissue disorder—Carmustine—malignant glioma	0.000479	0.00672	CcSEcCtD
Dabrafenib—Haemoglobin—Temozolomide—malignant glioma	0.000473	0.00664	CcSEcCtD
Dabrafenib—Haemorrhage—Temozolomide—malignant glioma	0.000471	0.00661	CcSEcCtD
Dabrafenib—Urinary tract disorder—Temozolomide—malignant glioma	0.000465	0.00653	CcSEcCtD
Dabrafenib—Oedema peripheral—Temozolomide—malignant glioma	0.000464	0.00651	CcSEcCtD
Dabrafenib—Connective tissue disorder—Temozolomide—malignant glioma	0.000463	0.00649	CcSEcCtD
Dabrafenib—Urethral disorder—Temozolomide—malignant glioma	0.000462	0.00648	CcSEcCtD
Dabrafenib—Eye disorder—Carmustine—malignant glioma	0.000455	0.00639	CcSEcCtD
Dabrafenib—Eye disorder—Temozolomide—malignant glioma	0.00044	0.00618	CcSEcCtD
Dabrafenib—Arrhythmia—Carmustine—malignant glioma	0.000435	0.00611	CcSEcCtD
Dabrafenib—Alopecia—Carmustine—malignant glioma	0.000431	0.00604	CcSEcCtD
Dabrafenib—Angiopathy—Temozolomide—malignant glioma	0.000427	0.006	CcSEcCtD
Dabrafenib—Mental disorder—Carmustine—malignant glioma	0.000427	0.00599	CcSEcCtD
Dabrafenib—Immune system disorder—Temozolomide—malignant glioma	0.000425	0.00597	CcSEcCtD
Dabrafenib—Mediastinal disorder—Temozolomide—malignant glioma	0.000424	0.00596	CcSEcCtD
Dabrafenib—Erythema—Carmustine—malignant glioma	0.000424	0.00595	CcSEcCtD
Dabrafenib—Malnutrition—Carmustine—malignant glioma	0.000424	0.00595	CcSEcCtD
Dabrafenib—Chills—Temozolomide—malignant glioma	0.000422	0.00593	CcSEcCtD
Dabrafenib—Alopecia—Temozolomide—malignant glioma	0.000416	0.00584	CcSEcCtD
Dabrafenib—Mental disorder—Temozolomide—malignant glioma	0.000413	0.00579	CcSEcCtD
Dabrafenib—Back pain—Carmustine—malignant glioma	0.00041	0.00576	CcSEcCtD
Dabrafenib—Malnutrition—Temozolomide—malignant glioma	0.00041	0.00575	CcSEcCtD
Dabrafenib—Erythema—Temozolomide—malignant glioma	0.00041	0.00575	CcSEcCtD
Dabrafenib—Vision blurred—Carmustine—malignant glioma	0.0004	0.00561	CcSEcCtD
Dabrafenib—Back pain—Temozolomide—malignant glioma	0.000396	0.00556	CcSEcCtD
Dabrafenib—Anaemia—Carmustine—malignant glioma	0.000392	0.0055	CcSEcCtD
Dabrafenib—Vision blurred—Temozolomide—malignant glioma	0.000386	0.00542	CcSEcCtD
Dabrafenib—SLC22A8—central nervous system—malignant glioma	0.000384	0.0081	CbGeAlD
Dabrafenib—Leukopenia—Carmustine—malignant glioma	0.00038	0.00533	CcSEcCtD
Dabrafenib—Anaemia—Temozolomide—malignant glioma	0.000379	0.00532	CcSEcCtD
Dabrafenib—ABCG2—medulla oblongata—malignant glioma	0.000378	0.00797	CbGeAlD
Dabrafenib—Leukopenia—Temozolomide—malignant glioma	0.000367	0.00515	CcSEcCtD
Dabrafenib—Hypertension—Carmustine—malignant glioma	0.000366	0.00514	CcSEcCtD
Dabrafenib—Myalgia—Carmustine—malignant glioma	0.000361	0.00507	CcSEcCtD
Dabrafenib—Cough—Temozolomide—malignant glioma	0.000358	0.00502	CcSEcCtD
Dabrafenib—Hypertension—Temozolomide—malignant glioma	0.000354	0.00497	CcSEcCtD
Dabrafenib—Myalgia—Temozolomide—malignant glioma	0.000349	0.0049	CcSEcCtD
Dabrafenib—Arthralgia—Temozolomide—malignant glioma	0.000349	0.0049	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000347	0.00486	CcSEcCtD
Dabrafenib—Oedema—Carmustine—malignant glioma	0.000346	0.00486	CcSEcCtD
Dabrafenib—ABCG2—midbrain—malignant glioma	0.000345	0.00728	CbGeAlD
Dabrafenib—Infection—Carmustine—malignant glioma	0.000344	0.00483	CcSEcCtD
Dabrafenib—Dry mouth—Temozolomide—malignant glioma	0.000341	0.00479	CcSEcCtD
Dabrafenib—Thrombocytopenia—Carmustine—malignant glioma	0.000339	0.00476	CcSEcCtD
Dabrafenib—ABCG2—spinal cord—malignant glioma	0.000337	0.0071	CbGeAlD
Dabrafenib—Oedema—Temozolomide—malignant glioma	0.000335	0.0047	CcSEcCtD
Dabrafenib—Infection—Temozolomide—malignant glioma	0.000332	0.00466	CcSEcCtD
Dabrafenib—Nervous system disorder—Temozolomide—malignant glioma	0.000328	0.0046	CcSEcCtD
Dabrafenib—Thrombocytopenia—Temozolomide—malignant glioma	0.000328	0.0046	CcSEcCtD
Dabrafenib—Skin disorder—Temozolomide—malignant glioma	0.000325	0.00456	CcSEcCtD
Dabrafenib—Hypotension—Carmustine—malignant glioma	0.000323	0.00454	CcSEcCtD
Dabrafenib—Hyperhidrosis—Temozolomide—malignant glioma	0.000323	0.00454	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000315	0.00443	CcSEcCtD
Dabrafenib—Insomnia—Carmustine—malignant glioma	0.000313	0.00439	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000305	0.00428	CcSEcCtD
Dabrafenib—SLC22A8—brain—malignant glioma	0.000305	0.00643	CbGeAlD
Dabrafenib—Insomnia—Temozolomide—malignant glioma	0.000303	0.00425	CcSEcCtD
Dabrafenib—Decreased appetite—Carmustine—malignant glioma	0.000301	0.00422	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Carmustine—malignant glioma	0.000299	0.00419	CcSEcCtD
Dabrafenib—Constipation—Carmustine—malignant glioma	0.000296	0.00415	CcSEcCtD
Dabrafenib—ABCB1—embryo—malignant glioma	0.000291	0.00615	CbGeAlD
Dabrafenib—Decreased appetite—Temozolomide—malignant glioma	0.000291	0.00408	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000289	0.00405	CcSEcCtD
Dabrafenib—Fatigue—Temozolomide—malignant glioma	0.000288	0.00405	CcSEcCtD
Dabrafenib—Constipation—Temozolomide—malignant glioma	0.000286	0.00402	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Carmustine—malignant glioma	0.000283	0.00397	CcSEcCtD
Dabrafenib—Body temperature increased—Carmustine—malignant glioma	0.000274	0.00384	CcSEcCtD
Dabrafenib—Abdominal pain—Carmustine—malignant glioma	0.000274	0.00384	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Temozolomide—malignant glioma	0.000274	0.00384	CcSEcCtD
Dabrafenib—ABCG2—cerebellum—malignant glioma	0.000267	0.00563	CbGeAlD
Dabrafenib—Abdominal pain—Temozolomide—malignant glioma	0.000264	0.00371	CcSEcCtD
Dabrafenib—Body temperature increased—Temozolomide—malignant glioma	0.000264	0.00371	CcSEcCtD
Dabrafenib—ABCB1—retina—malignant glioma	0.000258	0.00544	CbGeAlD
Dabrafenib—Hypersensitivity—Carmustine—malignant glioma	0.000255	0.00358	CcSEcCtD
Dabrafenib—Asthenia—Carmustine—malignant glioma	0.000248	0.00349	CcSEcCtD
Dabrafenib—Hypersensitivity—Temozolomide—malignant glioma	0.000246	0.00346	CcSEcCtD
Dabrafenib—Asthenia—Temozolomide—malignant glioma	0.00024	0.00337	CcSEcCtD
Dabrafenib—ABCB1—telencephalon—malignant glioma	0.000237	0.005	CbGeAlD
Dabrafenib—Diarrhoea—Carmustine—malignant glioma	0.000237	0.00332	CcSEcCtD
Dabrafenib—Pruritus—Temozolomide—malignant glioma	0.000237	0.00332	CcSEcCtD
Dabrafenib—Dizziness—Carmustine—malignant glioma	0.000229	0.00321	CcSEcCtD
Dabrafenib—Diarrhoea—Temozolomide—malignant glioma	0.000229	0.00321	CcSEcCtD
Dabrafenib—CYP2C8—brain—malignant glioma	0.000223	0.00471	CbGeAlD
Dabrafenib—Dizziness—Temozolomide—malignant glioma	0.000221	0.0031	CcSEcCtD
Dabrafenib—Vomiting—Carmustine—malignant glioma	0.00022	0.00309	CcSEcCtD
Dabrafenib—Rash—Carmustine—malignant glioma	0.000218	0.00306	CcSEcCtD
Dabrafenib—Dermatitis—Carmustine—malignant glioma	0.000218	0.00306	CcSEcCtD
Dabrafenib—Headache—Carmustine—malignant glioma	0.000217	0.00304	CcSEcCtD
Dabrafenib—ABCG2—brain—malignant glioma	0.000217	0.00458	CbGeAlD
Dabrafenib—Vomiting—Temozolomide—malignant glioma	0.000213	0.00299	CcSEcCtD
Dabrafenib—Rash—Temozolomide—malignant glioma	0.000211	0.00296	CcSEcCtD
Dabrafenib—Dermatitis—Temozolomide—malignant glioma	0.000211	0.00296	CcSEcCtD
Dabrafenib—Headache—Temozolomide—malignant glioma	0.00021	0.00294	CcSEcCtD
Dabrafenib—Nausea—Carmustine—malignant glioma	0.000206	0.00289	CcSEcCtD
Dabrafenib—Nausea—Temozolomide—malignant glioma	0.000199	0.00279	CcSEcCtD
Dabrafenib—CYP3A4—central nervous system—malignant glioma	0.00019	0.00402	CbGeAlD
Dabrafenib—ABCB1—medulla oblongata—malignant glioma	0.000186	0.00393	CbGeAlD
Dabrafenib—ABCB1—midbrain—malignant glioma	0.00017	0.00359	CbGeAlD
Dabrafenib—ABCB1—spinal cord—malignant glioma	0.000166	0.0035	CbGeAlD
Dabrafenib—ABCB1—central nervous system—malignant glioma	0.000135	0.00284	CbGeAlD
Dabrafenib—ABCB1—cerebellum—malignant glioma	0.000132	0.00278	CbGeAlD
Dabrafenib—ABCB1—brain—malignant glioma	0.000107	0.00226	CbGeAlD
Dabrafenib—RAF1—Immune System—BAD—malignant glioma	8.5e-06	6.11e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	8.49e-06	6.1e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CAV1—malignant glioma	8.44e-06	6.07e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PIK3CB—malignant glioma	8.41e-06	6.05e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KDR—malignant glioma	8.35e-06	6e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CAV1—malignant glioma	8.34e-06	5.99e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PTGS2—malignant glioma	8.34e-06	5.99e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—IDH1—malignant glioma	8.27e-06	5.95e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—malignant glioma	8.27e-06	5.94e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD80—malignant glioma	8.24e-06	5.92e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AKT2—malignant glioma	8.24e-06	5.92e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—malignant glioma	8.2e-06	5.89e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TNF—malignant glioma	8.2e-06	5.89e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NTRK1—malignant glioma	8.2e-06	5.89e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EGF—malignant glioma	8.13e-06	5.84e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—KRAS—malignant glioma	8.13e-06	5.84e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GSTP1—malignant glioma	8.13e-06	5.84e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PTPN11—malignant glioma	8.08e-06	5.81e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—NCOR1—malignant glioma	8.07e-06	5.8e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—F2—malignant glioma	8.03e-06	5.77e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FN1—malignant glioma	8.03e-06	5.77e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SPHK1—malignant glioma	8.01e-06	5.75e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—KRAS—malignant glioma	7.98e-06	5.73e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—BAD—malignant glioma	7.94e-06	5.71e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PIK3CD—malignant glioma	7.92e-06	5.69e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CAT—malignant glioma	7.91e-06	5.69e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NOTCH1—malignant glioma	7.86e-06	5.65e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—BAD—malignant glioma	7.84e-06	5.64e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP2C18—malignant glioma	7.84e-06	5.64e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PIK3CD—malignant glioma	7.84e-06	5.64e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ASMT—malignant glioma	7.82e-06	5.62e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NOTCH1—malignant glioma	7.77e-06	5.58e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	7.73e-06	5.56e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CD80—malignant glioma	7.7e-06	5.54e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—APC—malignant glioma	7.69e-06	5.53e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CG—malignant glioma	7.69e-06	5.53e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MMP3—malignant glioma	7.62e-06	5.48e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CD80—malignant glioma	7.61e-06	5.47e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—EGFR—malignant glioma	7.6e-06	5.46e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EGF—malignant glioma	7.6e-06	5.46e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—APC—malignant glioma	7.6e-06	5.46e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PTPN11—malignant glioma	7.55e-06	5.43e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CDKN2B—malignant glioma	7.55e-06	5.43e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—malignant glioma	7.54e-06	5.42e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—AKT2—malignant glioma	7.53e-06	5.41e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EGF—malignant glioma	7.51e-06	5.4e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—NCOR1—malignant glioma	7.47e-06	5.37e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTPN11—malignant glioma	7.46e-06	5.36e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	7.46e-06	5.36e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—BCAN—malignant glioma	7.35e-06	5.28e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTK2—malignant glioma	7.34e-06	5.27e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—PIK3CA—malignant glioma	7.33e-06	5.27e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—EGFR—malignant glioma	7.3e-06	5.25e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—malignant glioma	7.29e-06	5.24e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTT1—malignant glioma	7.28e-06	5.23e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PTEN—malignant glioma	7.27e-06	5.22e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PIK3CD—malignant glioma	7.23e-06	5.2e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HES1—malignant glioma	7.21e-06	5.18e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—KRAS—malignant glioma	7.18e-06	5.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NCOR1—malignant glioma	7.16e-06	5.15e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—BRAF—malignant glioma	7.14e-06	5.13e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TP53—malignant glioma	7.09e-06	5.1e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AKT2—malignant glioma	7.04e-06	5.06e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—AKT2—malignant glioma	6.95e-06	5e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—FGF2—malignant glioma	6.93e-06	4.98e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PIK3CB—malignant glioma	6.9e-06	4.96e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—KRAS—malignant glioma	6.9e-06	4.96e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PDGFRA—malignant glioma	6.86e-06	4.93e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PIK3CB—malignant glioma	6.84e-06	4.91e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS1—malignant glioma	6.82e-06	4.9e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	6.8e-06	4.89e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTGS2—malignant glioma	6.77e-06	4.87e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CD—malignant glioma	6.76e-06	4.86e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CD—malignant glioma	6.68e-06	4.8e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SPP1—malignant glioma	6.66e-06	4.79e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CXCL8—malignant glioma	6.63e-06	4.77e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—PIK3CA—malignant glioma	6.6e-06	4.74e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CAV1—malignant glioma	6.58e-06	4.73e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—BCL2—malignant glioma	6.58e-06	4.73e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IFNG—malignant glioma	6.52e-06	4.68e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—STAT3—malignant glioma	6.5e-06	4.67e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MDM2—malignant glioma	6.48e-06	4.66e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FGF2—malignant glioma	6.47e-06	4.65e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—FGF2—malignant glioma	6.39e-06	4.6e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ERBB2—malignant glioma	6.39e-06	4.59e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTT1—malignant glioma	6.34e-06	4.56e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—BCHE—malignant glioma	6.34e-06	4.56e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL2—malignant glioma	6.34e-06	4.55e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—PIK3CA—malignant glioma	6.34e-06	4.55e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TERT—malignant glioma	6.31e-06	4.54e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PIK3CB—malignant glioma	6.3e-06	4.53e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	6.29e-06	4.52e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—SLC5A5—malignant glioma	6.27e-06	4.5e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PDGFB—malignant glioma	6.16e-06	4.43e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—malignant glioma	6.16e-06	4.42e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGFR1—malignant glioma	6.13e-06	4.41e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—AKT1—malignant glioma	6.1e-06	4.39e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CAV1—malignant glioma	6.09e-06	4.38e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MDM2—malignant glioma	6.06e-06	4.35e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MYC—malignant glioma	6.04e-06	4.34e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HIF1A—malignant glioma	6.04e-06	4.34e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—RAF1—malignant glioma	6.03e-06	4.34e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CG—malignant glioma	5.99e-06	4.31e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—AKT1—malignant glioma	5.99e-06	4.3e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MDM2—malignant glioma	5.98e-06	4.3e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ERBB2—malignant glioma	5.97e-06	4.29e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS1—malignant glioma	5.94e-06	4.27e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—IDH2—malignant glioma	5.93e-06	4.26e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	5.93e-06	4.26e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—EGFR—malignant glioma	5.91e-06	4.25e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTEN—malignant glioma	5.91e-06	4.24e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—ERBB2—malignant glioma	5.9e-06	4.24e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CB—malignant glioma	5.89e-06	4.23e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	5.87e-06	4.22e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CAV1—malignant glioma	5.84e-06	4.2e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CB—malignant glioma	5.82e-06	4.18e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL1B—malignant glioma	5.81e-06	4.18e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL2—malignant glioma	5.79e-06	4.16e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PPARG—malignant glioma	5.78e-06	4.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KDR—malignant glioma	5.77e-06	4.15e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTGS2—malignant glioma	5.77e-06	4.14e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCL8—malignant glioma	5.66e-06	4.07e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—KRAS—malignant glioma	5.58e-06	4.01e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP2B6—malignant glioma	5.57e-06	4.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—F2—malignant glioma	5.56e-06	3.99e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FN1—malignant glioma	5.56e-06	3.99e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CG—malignant glioma	5.55e-06	3.99e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—BCHE—malignant glioma	5.53e-06	3.97e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—BAD—malignant glioma	5.49e-06	3.95e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SLC5A5—malignant glioma	5.46e-06	3.92e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PTEN—malignant glioma	5.45e-06	3.92e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOTCH1—malignant glioma	5.44e-06	3.91e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CASP3—malignant glioma	5.42e-06	3.89e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL2—malignant glioma	5.41e-06	3.89e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—AKT1—malignant glioma	5.39e-06	3.87e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PPARG—malignant glioma	5.36e-06	3.85e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CD80—malignant glioma	5.33e-06	3.83e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CG—malignant glioma	5.32e-06	3.82e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APC—malignant glioma	5.32e-06	3.82e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CD—malignant glioma	5.27e-06	3.79e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EGF—malignant glioma	5.26e-06	3.78e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTPN11—malignant glioma	5.23e-06	3.76e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—AKT1—malignant glioma	5.18e-06	3.72e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PIK3CA—malignant glioma	5.13e-06	3.69e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MMP9—malignant glioma	5.12e-06	3.68e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	5.12e-06	3.68e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—IDH1—malignant glioma	5.1e-06	3.66e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PTEN—malignant glioma	5.09e-06	3.66e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTP1—malignant glioma	5.05e-06	3.63e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTEN—malignant glioma	5.03e-06	3.61e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—RAF1—malignant glioma	5.03e-06	3.61e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—BRAF—malignant glioma	5e-06	3.59e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SPHK1—malignant glioma	4.93e-06	3.54e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CAT—malignant glioma	4.91e-06	3.53e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CD—malignant glioma	4.88e-06	3.51e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—STAT3—malignant glioma	4.87e-06	3.5e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AKT2—malignant glioma	4.87e-06	3.5e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—EGFR—malignant glioma	4.85e-06	3.48e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP2C18—malignant glioma	4.83e-06	3.47e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CD—malignant glioma	4.68e-06	3.36e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NCOR1—malignant glioma	4.64e-06	3.33e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VEGFA—malignant glioma	4.6e-06	3.3e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CB—malignant glioma	4.59e-06	3.3e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—KRAS—malignant glioma	4.58e-06	3.29e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—STAT3—malignant glioma	4.55e-06	3.27e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTGS2—malignant glioma	4.55e-06	3.27e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—STAT3—malignant glioma	4.5e-06	3.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGF2—malignant glioma	4.48e-06	3.22e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EGFR—malignant glioma	4.43e-06	3.18e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTP1—malignant glioma	4.4e-06	3.16e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CAT—malignant glioma	4.28e-06	3.07e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CB—malignant glioma	4.25e-06	3.06e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MYC—malignant glioma	4.23e-06	3.04e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTGS2—malignant glioma	4.21e-06	3.03e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PIK3CA—malignant glioma	4.21e-06	3.02e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—AKT1—malignant glioma	4.19e-06	3.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MDM2—malignant glioma	4.19e-06	3.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KRAS—malignant glioma	4.18e-06	3.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MYC—malignant glioma	4.18e-06	3e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PIK3CA—malignant glioma	4.17e-06	2.99e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EGFR—malignant glioma	4.14e-06	2.97e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ERBB2—malignant glioma	4.13e-06	2.97e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EGFR—malignant glioma	4.09e-06	2.94e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CB—malignant glioma	4.08e-06	2.93e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NCOR1—malignant glioma	4.04e-06	2.9e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTEN—malignant glioma	3.97e-06	2.85e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL8—malignant glioma	3.92e-06	2.82e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KRAS—malignant glioma	3.91e-06	2.81e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTT1—malignant glioma	3.91e-06	2.81e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—KRAS—malignant glioma	3.86e-06	2.78e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PIK3CA—malignant glioma	3.84e-06	2.76e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CAV1—malignant glioma	3.78e-06	2.72e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CASP3—malignant glioma	3.75e-06	2.69e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL2—malignant glioma	3.74e-06	2.69e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTEN—malignant glioma	3.67e-06	2.64e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS1—malignant glioma	3.66e-06	2.63e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	3.61e-06	2.6e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CA—malignant glioma	3.59e-06	2.58e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CA—malignant glioma	3.55e-06	2.55e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MMP9—malignant glioma	3.54e-06	2.55e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTEN—malignant glioma	3.52e-06	2.53e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—malignant glioma	3.47e-06	2.5e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CG—malignant glioma	3.44e-06	2.47e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AKT1—malignant glioma	3.44e-06	2.47e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—BCHE—malignant glioma	3.4e-06	2.45e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—AKT1—malignant glioma	3.4e-06	2.45e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC5A5—malignant glioma	3.36e-06	2.42e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PPARG—malignant glioma	3.32e-06	2.39e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CAV1—malignant glioma	3.29e-06	2.37e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VEGFA—malignant glioma	3.18e-06	2.29e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—STAT3—malignant glioma	3.15e-06	2.26e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—AKT1—malignant glioma	3.14e-06	2.26e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CD—malignant glioma	3.03e-06	2.18e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CG—malignant glioma	3e-06	2.16e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AKT1—malignant glioma	2.93e-06	2.11e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MYC—malignant glioma	2.93e-06	2.1e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—AKT1—malignant glioma	2.9e-06	2.08e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PPARG—malignant glioma	2.9e-06	2.08e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EGFR—malignant glioma	2.86e-06	2.06e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CA—malignant glioma	2.8e-06	2.01e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTP1—malignant glioma	2.71e-06	1.95e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KRAS—malignant glioma	2.7e-06	1.94e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CB—malignant glioma	2.64e-06	1.9e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CD—malignant glioma	2.64e-06	1.9e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CAT—malignant glioma	2.64e-06	1.89e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS2—malignant glioma	2.61e-06	1.88e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CA—malignant glioma	2.59e-06	1.86e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NCOR1—malignant glioma	2.49e-06	1.79e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CA—malignant glioma	2.48e-06	1.79e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—malignant glioma	2.4e-06	1.73e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CB—malignant glioma	2.3e-06	1.65e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AKT1—malignant glioma	2.29e-06	1.64e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTEN—malignant glioma	2.28e-06	1.64e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS2—malignant glioma	2.28e-06	1.64e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AKT1—malignant glioma	2.12e-06	1.52e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AKT1—malignant glioma	2.03e-06	1.46e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CAV1—malignant glioma	2.03e-06	1.46e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTEN—malignant glioma	1.99e-06	1.43e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CG—malignant glioma	1.85e-06	1.33e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPARG—malignant glioma	1.78e-06	1.28e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CD—malignant glioma	1.62e-06	1.17e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CA—malignant glioma	1.61e-06	1.16e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CB—malignant glioma	1.42e-06	1.02e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS2—malignant glioma	1.4e-06	1.01e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CA—malignant glioma	1.4e-06	1.01e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AKT1—malignant glioma	1.31e-06	9.44e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTEN—malignant glioma	1.22e-06	8.8e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AKT1—malignant glioma	1.14e-06	8.23e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CA—malignant glioma	8.63e-07	6.21e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AKT1—malignant glioma	7.05e-07	5.07e-06	CbGpPWpGaD
